Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
IMRX
IMRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest IMRX ETF News Today | Earnings, Events & Price Alerts
IMRX News
U.S. Stocks Rise on Venezuela Action; Chevron Shares Up 5.8%
Jan 10 2026
Benzinga
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
Jan 08 2026
Benzinga
Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026
Jan 08 2026
Benzinga
Immuneering Updates Pancreatic Cancer Trial Data, Survival Rates Show Significant Improvement
Jan 08 2026
Benzinga
Northrop Grumman Shares Rise 6.84% Following Military Budget Proposal
Jan 08 2026
Benzinga
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
Jan 08 2026
Benzinga
Immuneering Reports 64% Survival Rate in Phase 2a Trial for Pancreatic Cancer Drug
Jan 08 2026
NASDAQ.COM
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
Jan 07 2026
Benzinga
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
Dec 24 2025
Benzinga
Immuneering (IMRX) to Present 12-Month Survival Data for Atebimetinib in Pancreatic Cancer on January 7, 2026
Dec 24 2025
NASDAQ.COM
Immuneering Set to Launch Phase 3 Trial of Atebimetinib for Pancreatic Cancer by Mid-2026
Dec 18 2025
NASDAQ.COM
Immuneering Plans to Initiate Phase 3 Pancreatic Cancer Trial in Mid-2026
Dec 17 2025
Newsfilter
Immuneering to Join Nasdaq Biotechnology Index on December 22, 2025
Dec 16 2025
Newsfilter
Immuneering Set to Join the Nasdaq Biotechnology Index
Dec 16 2025
SeekingAlpha
Oncolytics Biotech Secures FDA Approval for Phase 3 Immunotherapy Trial in Pancreatic Cancer
Dec 12 2025
PRnewswire
Oncolytics Biotech Secures FDA Approval for Phase 3 Immunotherapy Trial in Pancreatic Cancer
Dec 12 2025
Newsfilter
Show More News
